June 13th 2025
In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the biosimilar market.
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
View More
Phentermine/Topiramate More Cost-Effective than Semaglutide for Teen Obesity
September 15th 2023This simulation study also showed that semaglutide was the most effective for weight loss, and researchers said, long-term, savings associated with potential lifelong health improvements may shift the balance of cost-effectiveness.
Read More
Dr. Benjamin Rome Discusses Ways to Address High Drug Prices
September 13th 2023Addressing drug affordability and accessibility will involve tackling the interrelated problems of high prices and problematic pharmacy benefit manager practices, says Benjamin N. Rome, M.D., with Brigham and Women’s Hospital in Boston.
Read More
Scripius Removes Dupixent from Formulary
September 7th 2023The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.
Read More
Switching to Long-Acting Injectable Paliperidone is Not Cost-Effective in Stable Schizophrenia
August 25th 2023Long-acting injection formulations of paliperidone improve health outcomes in adults with schizophrenia but that might not be enough to offset their substantial costs, new study finds.
Read More
Blue Shield of California to Work with Prime Therapeutics to Negotiate Drug Prices
August 18th 2023Blue Shield’s new program will unbundle pharmacy services for increased transparency with the goal of saving $500 million annually. The health plan is also teaming up Mark Cuban Cost Plus Drug Company and Amazon Pharmacy.
Read More
Tufts Evaluation Finds Health Plans Vary in Step Therapy for Camyzos
August 10th 2023Payers’ requirements for the use of Camyzos in patients with obstructive hypertrophic cardiomyopathy are generally consistent with the registration study, but they also imposed restrictions beyond the FDA indication or ICER recommendation.
Read More
Medicaid Coverage Increases for Pheburane for Urea Cycle Disorders
August 9th 2023Current treatments urea cycle disorders, which causes ammonia to build up in the blood, have a bitter taste and smell. Pheburane was developed with a special coating that masks the taste of sodium phenylbutyrate. It has a list price of $4,375 per bottle.
Read More